

Local Coverage Determination (LCD): RAST Type Tests (L33591)

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

Contractor Information

Contractor Name

[National Government Services, Inc.](#)

[Back to Top](#)

Contract Number

06201

Contract Type

MAC - Part A

LCD Information

Document Information

LCD ID

L33591

Original ICD-9 LCD ID

[L28463](#)

LCD Title

RAST Type Tests

AMA CPT / ADA CDT / AHA NUBC Copyright Statement
CPT only copyright 2002-2015 American Medical Association. All Rights Reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

The Code on Dental Procedures and Nomenclature (Code) is published in Current Dental Terminology (CDT). Copyright © American Dental Association. All rights reserved. CDT and CDT-2010 are trademarks of the American Dental Association.

UB-04 Manual. OFFICIAL UB-04 DATA SPECIFICATIONS MANUAL, 2014, is copyrighted by American Hospital Association ("AHA"), Chicago, Illinois. No portion of OFFICIAL UB-04 MANUAL may be reproduced, sorted in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior express, written consent of AHA." Health Forum reserves the right to change the copyright notice from time to time upon written notice to Company.

Jurisdiction

Minnesota

Original Effective Date

For services performed on or after 10/01/2015

Revision Effective Date

For services performed on or after 10/01/2015

Revision Ending Date

N/A

Retirement Date

N/A

Notice Period Start Date

N/A

Notice Period End Date

N/A

policy. NCDs and coverage provisions in interpretive manuals are not subject to the Local Coverage Determination (LCD) Review Process (42 CFR 405.860[b] and 42 CFR 426 [Subpart D]). In addition, an administrative law judge may not review an NCD. See Section 1869(f)(1)(A)(i) of the Social Security Act.

Unless otherwise specified, *italicized* text represents quotation from one or more of the following CMS sources:

Title XVIII of the Social Security Act (SSA):

Section 1862 (a)(1)(A) allows coverage and payment for only those services considered medically reasonable and necessary.

Section 1833 (e) prohibits Medicare payment for any claim which lacks the necessary information to process the claim.

Coverage Guidance

Coverage Indications, Limitations, and/or Medical Necessity

Abstract:

Radioallergosorbent test (RAST), fluoroallergosorbent test (FAST), and multiple antigen simultaneous tests are in vitro techniques for determining whether a patient's serum contains IgE antibodies against specific allergens of clinical importance. As with any allergy testing, the need for such tests is based on the findings during a complete history and physical examination of the patient.

The multiple antigen simultaneous testing technique is similar to the RAST/FAST techniques in that it depends upon the existence of allergic antibodies in the blood of the patient being tested. With the multiple antigen simultaneous test system, several antigens may be used to test for specific IgE simultaneously.

ELISA (enzyme-linked immunosorbent assay) is another in vitro method of allergy testing for specific IgE antibodies against allergens. This method is also a variation of RAST.

Limitations:

The following tests are considered to be not medically necessary and will be denied.

- ELISA/Act qualitative antibody testing
This testing is used to determine in vitro reaction to various foods and relies on lymphocyte blastogenesis in response to certain food antigens.
- LMRA (Lymphocyte Mitogen Response Assays) by ELISA/Act
- IgG ELISA, indirect method (CPT code 86001)
- Qualitative multi-allergen screen (CPT code 86005)
This is a non-specific test that does not identify a specific antigen.
- IgG and IgG subclass antibody tests for food allergy do not have clinical relevance, are not validated, lack sufficient quality control, and should not be performed.

[Back to Top](#)

Coding Information

Bill Type Codes:

Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the policy does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the policy should be assumed to apply equally to all claims.

011x Hospital Inpatient (Including Medicare Part A)

012x Hospital Inpatient (Medicare Part B only)

013x Hospital Outpatient
 014x Hospital - Laboratory Services Provided to Non-patients
 071x Clinic - Rural Health
 073x Clinic - Freestanding
 077x Clinic - Federally Qualified Health Center (FQHC)
 085x Critical Access Hospital

Revenue Codes:

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory; unless specified in the policy services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the policy should be assumed to apply equally to all Revenue Codes.

Revenue codes only apply to providers who bill these services to the Part A MAC. Revenue codes do not apply to physicians, other professionals and suppliers who bill these services to the Part B MAC.

Please note that not all revenue codes apply to every type of bill code. Providers are encouraged to refer to the FISS revenue code file for allowable bill types. Similarly, not all revenue codes apply to each CPT/HCPCS code. Providers are encouraged to refer to the FISS HCPCS file for allowable revenue codes.

All revenue codes billed on the inpatient claim for the dates of service in question may be subject to review.

0300 Laboratory - General Classification
 0302 Laboratory - Immunology
 0309 Laboratory - Other Laboratory
 0971 Professional Fees - Laboratory

CPT/HCPCS Codes

Group 1 Paragraph: CPT codes 86001 and 86005 are not covered services.

Group 1 Codes:

86001 ALLERGEN SPECIFIC IGG QUANTITATIVE OR SEMIQUANTITATIVE, EACH ALLERGEN
 86003 ALLERGEN SPECIFIC IGE; QUANTITATIVE OR SEMIQUANTITATIVE, EACH ALLERGEN
 86005 ALLERGEN SPECIFIC IGE; QUALITATIVE, MULTIALLERGEN SCREEN (DIPSTICK, PADDLE, OR DISK)

ICD-10 Codes that Support Medical Necessity

Group 1 Paragraph: The use of an ICD-10-CM code listed below does not assure coverage of a service. The service must be reasonable and necessary in the specific case and must meet the criteria specified in this determination.

The following ICD-10 Codes apply only to CPT code 86003:

Group 1 Codes:

ICD-10 Codes	Description
J30.0	Vasomotor rhinitis
J30.1	Allergic rhinitis due to pollen
J30.2	Other seasonal allergic rhinitis
J30.5	Allergic rhinitis due to food
J30.81	Allergic rhinitis due to animal (cat) (dog) hair and dander
J30.89	Other allergic rhinitis
J30.9	Allergic rhinitis, unspecified
J45.20	Mild intermittent asthma, uncomplicated
J45.21	Mild intermittent asthma with (acute) exacerbation
J45.22	Mild intermittent asthma with status asthmaticus
J45.30	Mild persistent asthma, uncomplicated

ICD-10 Codes	Description
J45.31	Mild persistent asthma with (acute) exacerbation
J45.32	Mild persistent asthma with status asthmaticus
J45.40	Moderate persistent asthma, uncomplicated
J45.41	Moderate persistent asthma with (acute) exacerbation
J45.42	Moderate persistent asthma with status asthmaticus
J45.50	Severe persistent asthma, uncomplicated
J45.51	Severe persistent asthma with (acute) exacerbation
J45.52	Severe persistent asthma with status asthmaticus
J45.901	Unspecified asthma with (acute) exacerbation
J45.902	Unspecified asthma with status asthmaticus
J45.909	Unspecified asthma, uncomplicated
J45.991	Cough variant asthma
J45.998	Other asthma
L20.0	Besnier's prurigo
L20.81	Atopic neurodermatitis
L20.82	Flexural eczema
L20.84	Intrinsic (allergic) eczema
L20.89	Other atopic dermatitis
L50.0	Allergic urticaria
L50.6	Contact urticaria
L50.8	Other urticaria
L50.9	Urticaria, unspecified
R06.2	Wheezing
T36.0X5A - T36.0X5S	Adverse effect of penicillins, initial encounter - Adverse effect of penicillins, sequela
T36.1X5A - T36.1X5S	Adverse effect of cephalosporins and other beta-lactam antibiotics, initial encounter - Adverse effect of cephalosporins and other beta-lactam antibiotics, sequela
T36.2X5A - T36.2X5S	Adverse effect of chloramphenicol group, initial encounter - Adverse effect of chloramphenicol group, sequela
T36.3X5A - T36.3X5S	Adverse effect of macrolides, initial encounter - Adverse effect of macrolides, sequela
T36.4X5A - T36.4X5S	Adverse effect of tetracyclines, initial encounter - Adverse effect of tetracyclines, sequela
T36.5X5A - T36.5X5S	Adverse effect of aminoglycosides, initial encounter - Adverse effect of aminoglycosides, sequela
T36.6X5A - T36.6X5S	Adverse effect of rifampicins, initial encounter - Adverse effect of rifampicins, sequela
T36.7X5A - T36.7X5S	Adverse effect of antifungal antibiotics, systemically used, initial encounter - Adverse effect of antifungal antibiotics, systemically used, sequela
T36.8X5A - T36.8X5S	Adverse effect of other systemic antibiotics, initial encounter - Adverse effect of other systemic antibiotics, sequela
T36.95XA - T36.95XS	Adverse effect of unspecified systemic antibiotic, initial encounter - Adverse effect of unspecified systemic antibiotic, sequela
T37.0X5A - T37.0X5S	Adverse effect of sulfonamides, initial encounter - Adverse effect of sulfonamides, sequela
T37.1X5A - T37.1X5S	Adverse effect of antimycobacterial drugs, initial encounter - Adverse effect of antimycobacterial drugs, sequela
T37.2X5A - T37.2X5S	Adverse effect of antimalarials and drugs acting on other blood protozoa, initial encounter - Adverse effect of antimalarials and drugs acting on other blood protozoa, sequela
T37.3X5A - T37.3X5S	Adverse effect of other antiprotozoal drugs, initial encounter - Adverse effect of other antiprotozoal drugs, sequela
T37.4X5A - T37.4X5S	Adverse effect of anthelmintics, initial encounter - Adverse effect of anthelmintics, sequela
T37.5X5A - T37.5X5S	Adverse effect of antiviral drugs, initial encounter - Adverse effect of antiviral drugs, sequela
T37.8X5A - T37.8X5S	Adverse effect of other specified systemic anti-infectives and antiparasitics, initial encounter - Adverse effect of other specified systemic anti-infectives and antiparasitics, sequela
T37.95XA - T37.95XS	Adverse effect of unspecified systemic anti-infective and antiparasitic, initial encounter - Adverse effect of unspecified systemic anti-infective and antiparasitic, sequela

ICD-10 Codes	Description
T38.0X5A - T38.0X5S	Adverse effect of glucocorticoids and synthetic analogues, initial encounter - Adverse effect of glucocorticoids and synthetic analogues, sequela
T38.1X5A - T38.1X5S	Adverse effect of thyroid hormones and substitutes, initial encounter - Adverse effect of thyroid hormones and substitutes, sequela
T38.2X5A - T38.2X5S	Adverse effect of antithyroid drugs, initial encounter - Adverse effect of antithyroid drugs, sequela
T38.4X5A - T38.4X5S	Adverse effect of oral contraceptives, initial encounter - Adverse effect of oral contraceptives, sequela
T38.5X5A - T38.5X5S	Adverse effect of other estrogens and progestogens, initial encounter - Adverse effect of other estrogens and progestogens, sequela
T38.6X5A - T38.6X5S	Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, initial encounter - Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, sequela
T38.7X5A - T38.7X5S	Adverse effect of androgens and anabolic congeners, initial encounter - Adverse effect of androgens and anabolic congeners, sequela
T38.805A - T38.805S	Adverse effect of unspecified hormones and synthetic substitutes, initial encounter - Adverse effect of unspecified hormones and synthetic substitutes, sequela
T38.815A - T38.815S	Adverse effect of anterior pituitary [adenohypophyseal] hormones, initial encounter - Adverse effect of anterior pituitary [adenohypophyseal] hormones, sequela
T38.895A - T38.895S	Adverse effect of other hormones and synthetic substitutes, initial encounter - Adverse effect of other hormones and synthetic substitutes, sequela
T38.905A - T38.905S	Adverse effect of unspecified hormone antagonists, initial encounter - Adverse effect of unspecified hormone antagonists, sequela
T38.995A - T38.995S	Adverse effect of other hormone antagonists, initial encounter - Adverse effect of other hormone antagonists, sequela
T39.015A - T39.015S	Adverse effect of aspirin, initial encounter - Adverse effect of aspirin, sequela
T39.095A - T39.095S	Adverse effect of salicylates, initial encounter - Adverse effect of salicylates, sequela
T39.1X5A - T39.1X5S	Adverse effect of 4-Aminophenol derivatives, initial encounter - Adverse effect of 4-Aminophenol derivatives, sequela
T39.2X5A - T39.2X5S	Adverse effect of pyrazolone derivatives, initial encounter - Adverse effect of pyrazolone derivatives, sequela
T39.315A - T39.315S	Adverse effect of propionic acid derivatives, initial encounter - Adverse effect of propionic acid derivatives, sequela
T39.395A - T39.395S	Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], initial encounter - Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], sequela
T39.4X5A - T39.4X5S	Adverse effect of antirheumatics, not elsewhere classified, initial encounter - Adverse effect of antirheumatics, not elsewhere classified, sequela
T39.8X5A - T39.8X5S	Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, initial encounter - Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, sequela
T39.95XA - T39.95XS	Adverse effect of unspecified nonopioid analgesic, antipyretic and antirheumatic, initial encounter - Adverse effect of unspecified nonopioid analgesic, antipyretic and antirheumatic, sequela
T40.0X5A - T40.0X5S	Adverse effect of opium, initial encounter - Adverse effect of opium, sequela
T40.2X5A - T40.2X5S	Adverse effect of other opioids, initial encounter - Adverse effect of other opioids, sequela
T40.3X5A - T40.3X5S	Adverse effect of methadone, initial encounter - Adverse effect of methadone, sequela
T40.4X5A - T40.4X5S	Adverse effect of other synthetic narcotics, initial encounter - Adverse effect of other synthetic narcotics, sequela
T40.5X5A - T40.5X5S	Adverse effect of cocaine, initial encounter - Adverse effect of cocaine, sequela
T40.605A - T40.605S	Adverse effect of unspecified narcotics, initial encounter - Adverse effect of unspecified narcotics, sequela
T40.695A - T40.695S	Adverse effect of other narcotics, initial encounter - Adverse effect of other narcotics, sequela
T40.7X5A - T40.7X5S	Adverse effect of cannabis (derivatives), initial encounter - Adverse effect of cannabis (derivatives), sequela

ICD-10 Codes	Description
T40.905A - T40.905S	Adverse effect of unspecified psychodysleptics [hallucinogens], initial encounter - Adverse effect of unspecified psychodysleptics [hallucinogens], sequela
T40.995A - T40.995S	Adverse effect of other psychodysleptics [hallucinogens], initial encounter - Adverse effect of other psychodysleptics [hallucinogens], sequela
T41.0X5A - T41.0X5S	Adverse effect of inhaled anesthetics, initial encounter - Adverse effect of inhaled anesthetics, sequela
T41.1X5A - T41.1X5S	Adverse effect of intravenous anesthetics, initial encounter - Adverse effect of intravenous anesthetics, sequela
T41.295A - T41.295S	Adverse effect of other general anesthetics, initial encounter - Adverse effect of other general anesthetics, sequela
T41.3X5A - T41.3X5S	Adverse effect of local anesthetics, initial encounter - Adverse effect of local anesthetics, sequela
T41.5X5A - T41.5X5S	Adverse effect of therapeutic gases, initial encounter - Adverse effect of therapeutic gases, sequela
T42.0X5A - T42.0X5S	Adverse effect of hydantoin derivatives, initial encounter - Adverse effect of hydantoin derivatives, sequela
T42.1X5A - T42.1X5S	Adverse effect of iminostilbenes, initial encounter - Adverse effect of iminostilbenes, sequela
T42.2X5A - T42.2X5S	Adverse effect of succinimides and oxazolidinediones, initial encounter - Adverse effect of succinimides and oxazolidinediones, sequela
T42.3X5A - T42.3X5S	Adverse effect of barbiturates, initial encounter - Adverse effect of barbiturates, sequela
T42.4X5A - T42.4X5S	Adverse effect of benzodiazepines, initial encounter - Adverse effect of benzodiazepines, sequela
T42.5X5A - T42.5X5S	Adverse effect of mixed antiepileptics, initial encounter - Adverse effect of mixed antiepileptics, sequela
T42.6X5A - T42.6X5S	Adverse effect of other antiepileptic and sedative-hypnotic drugs, initial encounter - Adverse effect of other antiepileptic and sedative-hypnotic drugs, sequela
T42.75XA - T42.75XS	Adverse effect of unspecified antiepileptic and sedative-hypnotic drugs, initial encounter - Adverse effect of unspecified antiepileptic and sedative-hypnotic drugs, sequela
T42.8X5A - T42.8X5S	Adverse effect of antiparkinsonism drugs and other central muscle-tone depressants, initial encounter - Adverse effect of antiparkinsonism drugs and other central muscle-tone depressants, sequela
T43.015A - T43.015S	Adverse effect of tricyclic antidepressants, initial encounter - Adverse effect of tricyclic antidepressants, sequela
T43.025A - T43.025S	Adverse effect of tetracyclic antidepressants, initial encounter - Adverse effect of tetracyclic antidepressants, sequela
T43.1X5A - T43.1X5S	Adverse effect of monoamine-oxidase-inhibitor antidepressants, initial encounter - Adverse effect of monoamine-oxidase-inhibitor antidepressants, sequela
T43.205A - T43.205S	Adverse effect of unspecified antidepressants, initial encounter - Adverse effect of unspecified antidepressants, sequela
T43.215A - T43.215S	Adverse effect of selective serotonin and norepinephrine reuptake inhibitors, initial encounter - Adverse effect of selective serotonin and norepinephrine reuptake inhibitors, sequela
T43.225A - T43.225S	Adverse effect of selective serotonin reuptake inhibitors, initial encounter - Adverse effect of selective serotonin reuptake inhibitors, sequela
T43.295A - T43.295S	Adverse effect of other antidepressants, initial encounter - Adverse effect of other antidepressants, sequela
T43.3X5A - T43.3X5S	Adverse effect of phenothiazine antipsychotics and neuroleptics, initial encounter - Adverse effect of phenothiazine antipsychotics and neuroleptics, sequela
T43.4X5A - T43.4X5S	Adverse effect of butyrophenone and thiothixene neuroleptics, initial encounter - Adverse effect of butyrophenone and thiothixene neuroleptics, sequela
T43.505A - T43.505S	Adverse effect of unspecified antipsychotics and neuroleptics, initial encounter - Adverse effect of unspecified antipsychotics and neuroleptics, sequela
T43.595A - T43.595S	Adverse effect of other antipsychotics and neuroleptics, initial encounter - Adverse effect of other antipsychotics and neuroleptics, sequela
T43.605A - T43.605S	Adverse effect of unspecified psychostimulants, initial encounter - Adverse effect of unspecified psychostimulants, sequela
T43.615A - T43.615S	Adverse effect of caffeine, initial encounter - Adverse effect of caffeine, sequela
T43.625A - T43.625S	Adverse effect of amphetamines, initial encounter - Adverse effect of amphetamines, sequela

ICD-10 Codes	Description
T43.635A - T43.635S	Adverse effect of methylphenidate, initial encounter - Adverse effect of methylphenidate, sequela
T43.695A - T43.695S	Adverse effect of other psychostimulants, initial encounter - Adverse effect of other psychostimulants, sequela
T43.8X5A - T43.8X5S	Adverse effect of other psychotropic drugs, initial encounter - Adverse effect of other psychotropic drugs, sequela
T43.95XA - T43.95XS	Adverse effect of unspecified psychotropic drug, initial encounter - Adverse effect of unspecified psychotropic drug, sequela
T44.0X5A - T44.0X5S	Adverse effect of anticholinesterase agents, initial encounter - Adverse effect of anticholinesterase agents, sequela
T44.1X5A - T44.1X5S	Adverse effect of other parasympathomimetics [cholinergics], initial encounter - Adverse effect of other parasympathomimetics [cholinergics], sequela
T44.2X5A - T44.2X5S	Adverse effect of ganglionic blocking drugs, initial encounter - Adverse effect of ganglionic blocking drugs, sequela
T44.3X5A - T44.3X5S	Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter - Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, sequela
T44.4X5A - T44.4X5S	Adverse effect of predominantly alpha-adrenoreceptor agonists, initial encounter - Adverse effect of predominantly alpha-adrenoreceptor agonists, sequela
T44.5X5A - T44.5X5S	Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter - Adverse effect of predominantly beta-adrenoreceptor agonists, sequela
T44.6X5A - T44.6X5S	Adverse effect of alpha-adrenoreceptor antagonists, initial encounter - Adverse effect of alpha-adrenoreceptor antagonists, sequela
T44.7X5A - T44.7X5S	Adverse effect of beta-adrenoreceptor antagonists, initial encounter - Adverse effect of beta-adrenoreceptor antagonists, sequela
T44.8X5A - T44.8X5S	Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, initial encounter - Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, sequela
T44.905A - T44.905S	Adverse effect of unspecified drugs primarily affecting the autonomic nervous system, initial encounter - Adverse effect of unspecified drugs primarily affecting the autonomic nervous system, sequela
T44.995A - T44.995S	Adverse effect of other drug primarily affecting the autonomic nervous system, initial encounter - Adverse effect of other drug primarily affecting the autonomic nervous system, sequela
T45.0X5A - T45.0X5S	Adverse effect of antiallergic and antiemetic drugs, initial encounter - Adverse effect of antiallergic and antiemetic drugs, sequela
T45.1X5A - T45.1X5S	Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter - Adverse effect of antineoplastic and immunosuppressive drugs, sequela
T45.2X5A - T45.2X5S	Adverse effect of vitamins, initial encounter - Adverse effect of vitamins, sequela
T45.3X5A - T45.3X5S	Adverse effect of enzymes, initial encounter - Adverse effect of enzymes, sequela
T45.4X5A - T45.4X5S	Adverse effect of iron and its compounds, initial encounter - Adverse effect of iron and its compounds, sequela
T45.515A - T45.515S	Adverse effect of anticoagulants, initial encounter - Adverse effect of anticoagulants, sequela
T45.525A - T45.525S	Adverse effect of antithrombotic drugs, initial encounter - Adverse effect of antithrombotic drugs, sequela
T45.605A - T45.605S	Adverse effect of unspecified fibrinolysis-affecting drugs, initial encounter - Adverse effect of unspecified fibrinolysis-affecting drugs, sequela
T45.615A - T45.615S	Adverse effect of thrombolytic drugs, initial encounter - Adverse effect of thrombolytic drugs, sequela
T45.625A - T45.625S	Adverse effect of hemostatic drug, initial encounter - Adverse effect of hemostatic drug, sequela
T45.695A - T45.695S	Adverse effect of other fibrinolysis-affecting drugs, initial encounter - Adverse effect of other fibrinolysis-affecting drugs, sequela
T45.7X5A - T45.7X5S	Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, initial encounter - Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, sequela
T45.8X5A - T45.8X5S	Adverse effect of other primarily systemic and hematological agents, initial encounter - Adverse effect of other primarily systemic and hematological agents, sequela
T45.95XA - T45.95XS	Adverse effect of unspecified primarily systemic and hematological agent, initial encounter - Adverse effect of unspecified primarily systemic and hematological agent, sequela

ICD-10 Codes	Description
T46.0X5A -	Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter -
T46.0X5S	Adverse effect of cardiac-stimulant glycosides and drugs of similar action, sequela
T46.1X5A -	Adverse effect of calcium-channel blockers, initial encounter - Adverse effect of calcium-channel
T46.1X5S	blockers, sequela
T46.2X5A -	Adverse effect of other antidysrhythmic drugs, initial encounter - Adverse effect of other
T46.2X5S	antidysrhythmic drugs, sequela
T46.3X5A -	Adverse effect of coronary vasodilators, initial encounter - Adverse effect of coronary vasodilators,
T46.3X5S	sequela
T46.4X5A -	Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter - Adverse effect of
T46.4X5S	angiotensin-converting-enzyme inhibitors, sequela
T46.5X5A -	Adverse effect of other antihypertensive drugs, initial encounter - Adverse effect of other
T46.5X5S	antihypertensive drugs, sequela
T46.6X5A -	Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter - Adverse
T46.6X5S	effect of antihyperlipidemic and antiarteriosclerotic drugs, sequela
T46.7X5A -	Adverse effect of peripheral vasodilators, initial encounter - Adverse effect of peripheral
T46.7X5S	vasodilators, sequela
T46.8X5A -	Adverse effect of antivaricose drugs, including sclerosing agents, initial encounter - Adverse effect
T46.8X5S	of antivaricose drugs, including sclerosing agents, sequela
T46.905A -	Adverse effect of unspecified agents primarily affecting the cardiovascular system, initial encounter
T46.905S	- Adverse effect of unspecified agents primarily affecting the cardiovascular system, sequela
T46.995A -	Adverse effect of other agents primarily affecting the cardiovascular system, initial encounter -
T46.995S	Adverse effect of other agents primarily affecting the cardiovascular system, sequela
T47.0X5A -	Adverse effect of histamine H2-receptor blockers, initial encounter - Adverse effect of histamine
T47.0X5S	H2-receptor blockers, sequela
T47.1X5A -	Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter - Adverse effect
T47.1X5S	of other antacids and anti-gastric-secretion drugs, sequela
T47.2X5A -	Adverse effect of stimulant laxatives, initial encounter - Adverse effect of stimulant laxatives,
T47.2X5S	sequela
T47.3X5A -	Adverse effect of saline and osmotic laxatives, initial encounter - Adverse effect of saline and
T47.3X5S	osmotic laxatives, sequela
T47.4X5A -	Adverse effect of other laxatives, initial encounter - Adverse effect of other laxatives, sequela
T47.4X5S	
T47.5X5A -	Adverse effect of digestants, initial encounter - Adverse effect of digestants, sequela
T47.5X5S	
T47.6X5A -	Adverse effect of antidiarrheal drugs, initial encounter - Adverse effect of antidiarrheal drugs,
T47.6X5S	sequela
T47.7X5A -	Adverse effect of emetics, initial encounter - Adverse effect of emetics, sequela
T47.7X5S	
T47.8X5A -	Adverse effect of other agents primarily affecting gastrointestinal system, initial encounter -
T47.8X5S	Adverse effect of other agents primarily affecting gastrointestinal system, sequela
T47.95XA -	Adverse effect of unspecified agents primarily affecting the gastrointestinal system, initial
T47.95XS	encounter - Adverse effect of unspecified agents primarily affecting the gastrointestinal system,
	sequela
T48.0X5A -	Adverse effect of oxytocic drugs, initial encounter - Adverse effect of oxytocic drugs, sequela
T48.0X5S	
T48.1X5A -	Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], initial encounter -
T48.1X5S	Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], sequela
T48.205A -	Adverse effect of unspecified drugs acting on muscles, initial encounter - Adverse effect of
T48.205S	unspecified drugs acting on muscles, sequela
T48.295A -	Adverse effect of other drugs acting on muscles, initial encounter - Adverse effect of other drugs
T48.295S	acting on muscles, sequela
T48.3X5A -	Adverse effect of antitussives, initial encounter - Adverse effect of antitussives, sequela
T48.3X5S	
T48.4X5A -	Adverse effect of expectorants, initial encounter - Adverse effect of expectorants, sequela
T48.4X5S	
T48.5X5A -	Adverse effect of other anti-common-cold drugs, initial encounter - Adverse effect of other anti-
T48.5X5S	common-cold drugs, sequela
T48.6X5A -	Adverse effect of antiasthmatics, initial encounter - Adverse effect of antiasthmatics, sequela
T48.6X5S	
T48.905A -	Adverse effect of unspecified agents primarily acting on the respiratory system, initial encounter -
T48.905S	Adverse effect of unspecified agents primarily acting on the respiratory system, sequela

ICD-10 Codes	Description
T48.995A -	Adverse effect of other agents primarily acting on the respiratory system, initial encounter -
T48.995S	Adverse effect of other agents primarily acting on the respiratory system, sequela
T49.0X5A -	Adverse effect of local antifungal, anti-infective and anti-inflammatory drugs, initial encounter -
T49.0X5S	Adverse effect of local antifungal, anti-infective and anti-inflammatory drugs, sequela
T49.1X5A -	Adverse effect of antipruritics, initial encounter -
T49.1X5S	Adverse effect of antipruritics, sequela
T49.2X5A -	Adverse effect of local astringents and local detergents, initial encounter -
T49.2X5S	Adverse effect of local astringents and local detergents, sequela
T49.3X5A -	Adverse effect of emollients, demulcents and protectants, initial encounter -
T49.3X5S	Adverse effect of emollients, demulcents and protectants, sequela
T49.4X5A -	Adverse effect of keratolytics, keratoplastics, and other hair treatment drugs and preparations, initial encounter -
T49.4X5S	Adverse effect of keratolytics, keratoplastics, and other hair treatment drugs and preparations, sequela
T49.5X5A -	Adverse effect of ophthalmological drugs and preparations, initial encounter -
T49.5X5S	Adverse effect of ophthalmological drugs and preparations, sequela
T49.6X5A -	Adverse effect of otorhinolaryngological drugs and preparations, initial encounter -
T49.6X5S	Adverse effect of otorhinolaryngological drugs and preparations, sequela
T49.7X5A -	Adverse effect of dental drugs, topically applied, initial encounter -
T49.7X5S	Adverse effect of dental drugs, topically applied, sequela
T49.8X5A -	Adverse effect of other topical agents, initial encounter -
T49.8X5S	Adverse effect of other topical agents, sequela
T49.95XA -	Adverse effect of unspecified topical agent, initial encounter -
T49.95XS	Adverse effect of unspecified topical agent, sequela
T50.0X5A -	Adverse effect of mineralocorticoids and their antagonists, initial encounter -
T50.0X5S	Adverse effect of mineralocorticoids and their antagonists, sequela
T50.1X5A -	Adverse effect of loop [high-ceiling] diuretics, initial encounter -
T50.1X5S	Adverse effect of loop [high-ceiling] diuretics, sequela
T50.2X5A -	Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, initial encounter -
T50.2X5S	Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, sequela
T50.3X5A -	Adverse effect of electrolytic, caloric and water-balance agents, initial encounter -
T50.3X5S	Adverse effect of electrolytic, caloric and water-balance agents, sequela
T50.4X5A -	Adverse effect of drugs affecting uric acid metabolism, initial encounter -
T50.4X5S	Adverse effect of drugs affecting uric acid metabolism, sequela
T50.5X5A -	Adverse effect of appetite depressants, initial encounter -
T50.5X5S	Adverse effect of appetite depressants, sequela
T50.6X5A -	Adverse effect of antidotes and chelating agents, initial encounter -
T50.6X5S	Adverse effect of antidotes and chelating agents, sequela
T50.7X5A -	Adverse effect of analeptics and opioid receptor antagonists, initial encounter -
T50.7X5S	Adverse effect of analeptics and opioid receptor antagonists, sequela
T50.8X5A -	Adverse effect of diagnostic agents, initial encounter -
T50.8X5S	Adverse effect of diagnostic agents, sequela
T50.A15A -	Adverse effect of pertussis vaccine, including combinations with a pertussis component, initial encounter -
T50.A15S	Adverse effect of pertussis vaccine, including combinations with a pertussis component, sequela
T50.A25A -	Adverse effect of mixed bacterial vaccines without a pertussis component, initial encounter -
T50.A25S	Adverse effect of mixed bacterial vaccines without a pertussis component, sequela
T50.A95A -	Adverse effect of other bacterial vaccines, initial encounter -
T50.A95S	Adverse effect of other bacterial vaccines, sequela
T50.B15A -	Adverse effect of smallpox vaccines, initial encounter -
T50.B15S	Adverse effect of smallpox vaccines, sequela
T50.B95A -	Adverse effect of other viral vaccines, initial encounter -
T50.B95S	Adverse effect of other viral vaccines, sequela
T50.Z15A -	Adverse effect of immunoglobulin, initial encounter -
T50.Z15S	Adverse effect of immunoglobulin, sequela
T50.Z95A -	Adverse effect of other vaccines and biological substances, initial encounter -
T50.Z95S	Adverse effect of other vaccines and biological substances, sequela
T50.905A -	Adverse effect of unspecified drugs, medicaments and biological substances, initial encounter -
T50.905S	Adverse effect of unspecified drugs, medicaments and biological substances, sequela
T50.995A -	Adverse effect of other drugs, medicaments and biological substances, initial encounter -
T50.995S	Adverse effect of other drugs, medicaments and biological substances, sequela

ICD-10 Codes	Description
T63.011A - T63.044S	Toxic effect of rattlesnake venom, accidental (unintentional), initial encounter - Toxic effect of cobra venom, undetermined, sequela
T63.061A - T63.094S	Toxic effect of venom of other North and South American snake, accidental (unintentional), initial encounter - Toxic effect of venom of other snake, undetermined, sequela
T63.111A - T63.124S	Toxic effect of venom of gila monster, accidental (unintentional), initial encounter - Toxic effect of venom of other venomous lizard, undetermined, sequela
T63.191A - T63.194S	Toxic effect of venom of other reptiles, accidental (unintentional), initial encounter - Toxic effect of venom of other reptiles, undetermined, sequela
T63.2X1A - T63.2X4S	Toxic effect of venom of scorpion, accidental (unintentional), initial encounter - Toxic effect of venom of scorpion, undetermined, sequela
T63.311A - T63.334S	Toxic effect of venom of black widow spider, accidental (unintentional), initial encounter - Toxic effect of venom of brown recluse spider, undetermined, sequela
T63.391A - T63.394S	Toxic effect of venom of other spider, accidental (unintentional), initial encounter - Toxic effect of venom of other spider, undetermined, sequela
T63.411A - T63.484S	Toxic effect of venom of centipedes and venomous millipedes, accidental (unintentional), initial encounter - Toxic effect of venom of other arthropod, undetermined, sequela
T63.511A - T63.514S	Toxic effect of contact with stingray, accidental (unintentional), initial encounter - Toxic effect of contact with stingray, undetermined, sequela
T63.591A - T63.594S	Toxic effect of contact with other venomous fish, accidental (unintentional), initial encounter - Toxic effect of contact with other venomous fish, undetermined, sequela
T63.611A - T63.634S	Toxic effect of contact with Portugese Man-o-war, accidental (unintentional), initial encounter - Toxic effect of contact with sea anemone, undetermined, sequela
T63.691A - T63.694S	Toxic effect of contact with other venomous marine animals, accidental (unintentional), initial encounter - Toxic effect of contact with other venomous marine animals, undetermined, sequela
T63.711A - T63.714S	Toxic effect of contact with venomous marine plant, accidental (unintentional), initial encounter - Toxic effect of contact with venomous marine plant, undetermined, sequela
T63.791A - T63.794S	Toxic effect of contact with other venomous plant, accidental (unintentional), initial encounter - Toxic effect of contact with other venomous plant, undetermined, sequela
T63.811A - T63.834S	Toxic effect of contact with venomous frog, accidental (unintentional), initial encounter - Toxic effect of contact with other venomous amphibian, undetermined, sequela
T63.891A - T63.894S	Toxic effect of contact with other venomous animals, accidental (unintentional), initial encounter - Toxic effect of contact with other venomous animals, undetermined, sequela
T78.00XA - T78.00XS	Anaphylactic reaction due to unspecified food, initial encounter - Anaphylactic reaction due to unspecified food, sequela
T78.01XA - T78.09XS	Anaphylactic reaction due to peanuts, initial encounter - Anaphylactic reaction due to other food products, sequela
T78.2XXA - T78.3XXS	Anaphylactic shock, unspecified, initial encounter - Angioneurotic edema, sequela
T78.40XA - T78.40XS	Allergy, unspecified, initial encounter - Allergy, unspecified, sequela
T78.49XA - T78.49XS	Other allergy, initial encounter - Other allergy, sequela
T88.6XXA - T88.6XXS	Anaphylactic reaction due to adverse effect of correct drug or medicament properly administered, initial encounter - Anaphylactic reaction due to adverse effect of correct drug or medicament properly administered, sequela
Z91.048	Other nonmedicinal substance allergy status
Z91.09	Other allergy status, other than to drugs and biological substances

ICD-10 Codes that DO NOT Support Medical Necessity N/A
ICD-10 Additional Information

[Back to Top](#)

[General Information](#)

Associated Information

Documentation Requirements:

The patient's medical record must contain documentation that fully supports the medical necessity for services included within this LCD. (See "Indications and Limitations of Coverage.") This documentation includes, but is not limited to, relevant medical history, physical examination, and results of pertinent diagnostic tests or procedures.

Each claim must be submitted with ICD-10-CM codes that reflect the condition of the patient, and indicate the reason(s) for which the service was performed. Claims submitted without ICD-10-CM codes will be returned.

Documentation must be available to Medicare upon request.

Utilization Guidelines:

It is expected that these services would be performed as indicated by current medical literature and/or standards of practice. When services are performed in excess of established parameters, they may be subject to review for medical necessity.

Sources of Information and Basis for Decision

This bibliography presents those sources that were obtained during the development of this policy. National Government Services is not responsible for the continuing viability of Web site addresses listed below.

Adkinson NF, Yunginger JW, Busse WW, et al *Middleton's Allergy: Principles and Practice*, 6th ed.

American College of Asthma, Allergy & Immunology (ACAAI). *Practice Parameters for Allergy Diagnostic Testing*. 1998.

Bernstein LI, Li JT, Bernstein DI et al, *Practice Parameters for Allergy Diagnostic Testing: An Updated Practice Parameter*. March 2008;100:S1-S148.

[Back to Top](#)

Revision History Information

Please note: Most Revision History entries effective on or before 01/24/2013 display with a Revision History Number of "R1" at the bottom of this table. However, there may be LCDs where these entries will display as a separate and distinct row.

Revision History Date	Revision History Number	Revision History Explanation	Reason(s) for Change
10/01/2015	R3	The ICD-10 range T78.01XA-T78.49XS has been broken out to remove ICD-10 codes T78.1XXA-T78.1XXS and T78.41XA-T78.41XS.	<ul style="list-style-type: none">• Revisions Due To ICD-10-CM Code Changes
10/01/2015	R2		<ul style="list-style-type: none">• Revisions Due To ICD-10-CM Code Changes

Revision History Date	Revision History Number	Revision History Explanation	Reason(s) for Change
10/01/2015 R1		The following ICD-10 codes have been removed: T63.91XA - T63.94XA and T88.59XA. Add Bill type codes	• Other

[Back to Top](#)

Associated Documents

Attachments N/A

Related Local Coverage Documents N/A

Related National Coverage Documents N/A

Public Version(s) Updated on 09/13/2015 with effective dates 10/01/2015 - N/A [Updated on 08/07/2015 with effective dates 10/01/2015 - N/A](#) [Updated on 07/13/2015 with effective dates 10/01/2015 - N/A](#) [Updated on 04/02/2014 with effective dates 10/01/2015 - N/A](#) [Back to Top](#)

Keywords

N/A Read the [LCD Disclaimer](#) [Back to Top](#)